VCTX210
Type 1 Diabetes
PreclinicalPreclinical
Key Facts
About CRISPR Therapeutics
CRISPR Therapeutics' mission is to develop curative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its landmark achievement is the approval of CASGEVY™ (exa-cel), the world's first CRISPR-based therapy, developed with Vertex Pharmaceuticals for sickle cell disease and beta thalassemia. The company's strategy leverages a fully integrated R&D and manufacturing infrastructure to advance a diversified clinical pipeline, including allogeneic CAR-T therapies for oncology and programs in regenerative medicine. CRISPR Therapeutics aims to sustain its first-mover advantage by expanding the applications of gene editing across multiple therapeutic areas.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |